Simon Hill

06/06/2026

on inflammation in the latest episode of 🙏🏼

Listen on all platforms - search The Proof with Simon Hill

06/05/2026

A lot of people think discipline and willpower is the missing link. If only someone could have more willpower they wouldn’t need a GLP-1. I asked about this in the latest episode of .

Listen now on YouTube, Spotify or Apple Podcasts.

06/03/2026

Yes weight comes back when you stop a GLP-1 but that’s not really a strong argument against them. When you look at data on dietary interventions - most people regain 80% of weight lost within a few years. Unfortunately, in the current food environment, it’s unrealistic to expect the population at large to change their diet and sustain those changes long term. GLP-1/GIP/Glucagon RAs are unique in that they reduce food noise making it possible for people to consume less calories in an environment that is built for overconsumption.

No solution is perfect.

The question to ask is. Is it healthier to be obese for decades or on a GLP-1 for decades at a healthy body weight? Best data we have suggests the latter.

05/12/2026

The most encouraging trend in longevity right now: at any given age, your risk of dementia is lower than it was 40 years ago.

A 90-year-old in 2024 has less than half the dementia risk of a 90-year-old in 1984 (Stallard et al, JAMA 2025). And it’s been replicated — Framingham Heart Study, Rotterdam Study, the Alzheimer Cohorts Consortium. Different countries, different cohorts, same direction.

Two things commonly get confused here, so this brief walks through both: PREVALENCE (how many people have dementia — rising, because the population is older) versus INCIDENCE (a given individual’s annual risk — falling).

And no — this isn’t because people are dying of heart disease earlier. US cardiovascular mortality has fallen by about 75% since 1950. People are living longer AND their per-age risk of dementia is dropping. Both improving together.

Why? The 2024 Lancet Commission identified 14 modifiable risk factors that together account for around 45% of dementia cases worldwide. The drivers map onto exactly the things we’ve been getting better at — blood pressure, smoking, education, hearing, lipids, glucose.

And with the rise of GLP-1s — and the next generation of dual and triple receptor agonists targeting obesity at scale — there’s a credible case the trend could accelerate further. Phase 2 and real-world data are promising. Phase 3 EVOKE in already-symptomatic Alzheimer’s was negative, which is an important caveat — primary prevention is a different question.

For the full evidence-based prevention protocol, listen to my conversation with preventive neurologist, Dr Kellyann Niotis — EP #337.

05/11/2026

USC Longevity Scientist Dr. Valter Longo: Why Growth Hormone Peptides Age You Faster

The peptide boom has moved from niche bodybuilding circles into mainstream wellness, GLP-1s are being treated as the perfect drug for almost everyone, and bi...

05/06/2026

Life of late. Podcasts and soul filling things. 🫶🏼

New episode with Harvard scientist .glenn.rd out on YouTube, Apple and Spotify podcasts.

05/06/2026

Two guidelines. One country. They don’t say the same thing.

The American Heart Association just published its 2026 dietary guidance for cardiovascular health.

The federal Dietary Guidelines for Americans 2025–2030 (sometimes called the “Real Food” guidelines) are also in effect.

Most of the message lines up — vegetables, fruits, whole grains, less added sugar, less sodium, less alcohol.

Both even agree to limit ultraprocessed foods (the federal version renames them “highly processed foods” but the directional advice is similar).

Where they actually split:

→ Protein source. AHA: shift from meat to plants — legumes, nuts, seeds, soy, fish. Federal: animal sources listed first, plants last. No clear preference.

→ Dairy. AHA: low-fat or fat-free preferred. Federal: full-fat dairy at 3 servings/day — a clear reversal of decades of low-fat guidance.

→ Saturated fat. Both kept the 10%-of-calories cap. But the federal guidelines simultaneously promote butter, beef tallow, and full-fat dairy as “healthy fats” in the new pyramid graphic.

These documents shape school lunches, hospital menus, SNAP and WIC standards, clinical advice, and nutrition research funding. They are not just words.

The cardiovascular evidence on plant-vs-animal protein and on full-fat vs low-fat dairy points the direction the AHA points.

📊 Quick poll — drop your answer in the comments:

🅰️ I’m following the AHA

🅱️ I’m following the federal “Real Food” guidelines

🅲 I follow my own framework based on the evidence

🅳 I had no idea these two disagreed

Curious where this community lands. No judgement — just want to see the split.

🎙️ Full breakdown on EP. 409 — The Dietary Guidelines Great Debate with Dr Christopher Gardner (Stanford, 2025 DGAC) and Dr Ty Beal (GAIN). On The Proof Podcast — link in bio.

👇 Reading-like-a-scientist toolkit in the comments.

05/05/2026

Dr Andrea Glenn is an Assistant Professor at NYU and a Visiting Scientist at Harvard. She’s a registered dietitian. And in this conversation, we cut through the noise on the questions you actually care about:

→ Are seed oils harming you, or are they protective?

→ Is butter “back,” or did the science never say what the influencers claimed?

→ Are low-carb diets the answer for diabetes, or do they make it worse depending on what you eat?

→ What does 30 years of cohort data actually show about the diets that protect against heart disease?

→ And how did the new American Heart Association guidance just publicly break with the Federal Dietary Guidelines on salt and red meat?

We also get into the diet that’s been shown to lower LDL cholesterol nearly as much as a low-dose statin — and the trial that’s about to test whether it actually prevents heart attacks.
This is the conversation for anyone who’s tired of being told what to eat by someone with a microphone and a strong opinion. The stakes couldn’t be higher. The conversation online has never been more confused. Today we cut through it.

🎧 Episode 416 — out now.

Search “The Proof with Simon Hill” on YouTube, Apple Podcasts, or Spotify and look for Episode 416 with Dr Andrea Glenn.

Save this post and share it with someone who needs to hear this.

04/30/2026

Peptides are having a moment.

Influencers and “wellness clinic” doctors are selling experimental peptides as the next biohacking frontier — for muscle, recovery, sleep, libido, longevity, you name it. CJC-1295. Ipamorelin. BPC-157. The list keeps growing.

Here’s what’s actually going on:

— The GLP-1 halo effect. GLP-1 receptor agonists went through decades of large human trials. They work. The brain takes that and generalises: if one peptide works, all peptides must. That’s not how evidence works. Each compound stands on its own trials.

— The evidence gap is real. The GLP-1 family — including dual and triple agonists — has 60,000+ trial participants and a decade of follow-up. BPC-157, the most-marketed of the lot, has roughly 30 human subjects across all published trials. Same broad chemical class. Completely different evidence base.

— “Big Pharma is threatened” is a marketing tool, not an evidence base. Pharma gets excited when early data looks promising — they’ve invested billions in peptide drugs (insulin, GLP-1s) when it justified the cost. BPC-157 was first described in 1991. CJC-1295 in the early 2000s. Industry has had 20–30 years to follow up. They mostly haven’t, because the later-stage risk-to-reward looks unfavourable. That’s the system working, not failing.

— The grey market is the real risk. In 2023, the FDA placed BPC-157, CJC-1295, and several others on its Category 2 list, citing insufficient evidence of safety in humans. In 2026, the HHS announced 12 peptides moving off Category 2, with PCAC review beginning July 2026. What this changes: where the grift happens. What it doesn’t change: the evidence base. No new RCTs. No new long-term human safety data. Same compounds. Different storefront.

This isn’t anti-peptide. Insulin is a peptide. GLP-1s are peptides. Real clinical use is real. The point is to distinguish what’s been properly studied from what hasn’t.

Don’t let DIY medicine become something you regret later in life.

Are you taking experimental peptides?